Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that Roche Group and Merck KGaA will emerge as players in the solid tumor drug market. According to the new report entitled Solid Tumor Pipeline Analysis: A New Market Leader Emerges, Roche's market share will grow from 12% in 2003 to 20% in 2008.

"Roche is developing a strong oncology franchise through its relationship with Genentech," said Heather Martin, analyst at Decision Resources. "As of December 2003, Roche owns 58.4% of Genentech's outstanding common stock. Genentech's antibody product line of Herceptin and Avastin will give Roche a leading role in oncology."

Merck KGaA will enter the solid tumor market mostly as a result of its collaboration with ImClone and Bristol-Myers Squibb for Erbitux for colorectal cancer. Smaller companies such as Dendreon, EntreMed, and Introgen Therapeutics will also enter the market by 2008 with products for solid tumors.

About DR Pipeline Reports from Decision Resources

DR Pipeline Reports is a series of comprehensive reports that focuses on pharmaceutical and biotech company drug development and commercialization strategies. Geared toward business development decision makers in the pharmaceutical, biotech, and financial industries, the DR Pipeline Reports expose major players in a therapeutic market and, more importantly, shed light on the emerging players that could significantly impact the current market once their pipelines are launched.

About Decision Resources

Decision Resources, Inc., ( is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Benefits of Current Therapeutic Options for Pancreatic Cancer are Eclipsed by Their Toxicity and Inconvenience in Advanced Stages of the Disease

View Now